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http://www.retrovirology.com/content/10/1/27RESEARCH Open AccessThe efficiency of Vpx-mediated SAMHD1
antagonism does not correlate with the potency
of viral control in HIV-2-infected individuals
Hangxing Yu1, Shariq M Usmani1, Alexandra Borch1, Julia Krämer1, Christina M Stürzel1, Mohammad Khalid1,
Xuehua Li1, Daniela Krnavek1, Marchina E van der Ende2, Albert D Osterhaus3, Rob A Gruters3 and Frank Kirchhoff1*Background: The presence of a vpx gene distinguishes HIV-2 from HIV-1, the main causative agent of AIDS. Vpx
degrades the restriction factor SAMHD1 to boost HIV-2 infection of macrophages and dendritic cells and it has
been suggested that the activation of antiviral innate immune responses after Vpx-dependent infection of myeloid
cells may explain why most HIV-2-infected individuals efficiently control viral replication and become long-term
survivors. However, the role of Vpx-mediated SAMHD1 antagonism in the virological and clinical outcome of HIV-2
infection remained to be investigated.
Results: Here, we analyzed the anti-SAMHD1 activity of vpx alleles derived from seven viremic and four long-term
aviremic HIV-2-infected individuals. We found that effective Vpx-mediated SAMHD1 degradation and enhancement
of myeloid cell infection was preserved in most HIV-2-infected individuals including all seven that failed to control
the virus and developed AIDS. The only exception were vpx alleles from an aviremic individual that predicted a
M68K change in a highly conserved nuclear localization signal which disrupted the ability of Vpx to counteract
SAMHD1. We also found that HIV-2 is less effective than HIV-1 in inducing innate immune activation in dendritic
cells.
Conclusions: Effective immune control of viral replication in HIV-2-infected individuals is not associated with
increased Vpx-mediated degradation of SAMHD1.
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SAM domain and HD domain-containing protein 1
(SAMHD1), the product of a gene linked to a rare
and severe inherited autoimmune disease named
Aicardi-Goutières syndrome [1], has recently been iden-
tified as the cellular factor that prevents HIV-1 infection
in dendritic cells and macrophages [2-4]. SAMHD1 is a
dGTP-stimulated triphosphohydrolase that converts
deoxynucleoside triphosphates (dNTPs) to deoxynu-
cleoside and inorganic triphosphate [5,6]. Thus, in con-
trast to other antiretroviral host restriction factors, such
as TRIM-5alpha, ABOPEC3G proteins, and tetherin
[7-9], SAMHD1 does not directly target viral compo-
nents to suppress viral replication but seems to restrict* Correspondence: frank.kirchhoff@uni-ulm.de
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reproduction in any medium, provided the orHIV-1 infection of non-dividing cells by decreasing the
dNTP pool concentration below the threshold required
for effective reverse transcription [10,11].
A variety of primate lentiviruses has evolved effective
antagonists of SAMHD1. The SIVsmm/HIV-2 lineage
and SIVs infecting drills and mandrills use their Vpx
protein to induce proteolytic degradation of SAMHD1
through the CUL4A/DCAF1 E3 ubiquitin ligase complex
[2-4,12-14]. Furthermore, phylogenetically distinct Vpr
proteins of SIVs infecting De Brazza`s, Mustached,
Grivet and Vervet monkeys also evolved the capability
of antagonizing SAMHD1 [13]. In contrast, HIV-1 and
its direct simian counterpart (SIVcpz infecting chimpan-
zees) do not encode Vpx [15] and the HIV-1 Vpr protein
does apparently not counteract SAMHD1-mediated re-
striction [3,4]. It has been reported that HIV-1 is effect-
ively sensed by infected dendritic cells to initiate a
potent antiviral immune response if the resistance ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ery of Vpx [16]. Viral sensing was dependent on the
interaction of newly synthesized viral p24 capsid protein
with cyclophylin A (CypA) and involved phosphorylation
of IRF3 [16]. Thus, HIV-1 may not have evolved an an-
tagonist of SAMHD1 to avoid infection of myeloid cells
and thus to escape from immune surveillance [16].
In contrast to HIV-1-infected individuals, the majority
of individuals infected with HIV-2 develop broad and ef-
fective humoral and cellular immune responses [17-20]
and become long-term non-progressors with undetect-
able viral loads [21-24]. As a consequence, the incidence
of HIV-2 infection is declining, while HIV-1 continues
to expand globally [25]. HIV-2 encodes Vpx and it has
been reported that this virus can efficiently infect and
activate monocyte-derived dendritic cells in a CypA de-
pendent manner [16]. These results raise the possibility
that efficient virus infection of myeloid cells due to po-
tent Vpx-mediated antagonism of SAMHD1 may acti-
vate protective immune responses and play a role in the
control of viral loads in HIV-2-infected individuals [16].
To address this issue, we examined the functional activ-
ity of twenty vpx alleles derived from eleven HIV-2-
infected individuals that differed drastically in the
control of viral replication. Our analyses showed that
most vpx alleles from both seven highly viremic and four
long-term aviremic HIV-2-infected individuals efficiently
degrade SAMHD1 and promote macrophage infection.
The only exception were two vpx alleles from HIV-2 iso-
lates derived from an aviremic patient (RH2-3) [26]. Both
predicted a K68M mutation in a nuclear localization motif
that disrupted the SAMHD1 degradation function. We also
examined the effect of HIV-1 and HIV-2 on dendritic cellTable 1 Overview on HIV-2 samples analyzed
Subject Clones CD4a PVLb Groupc
RH2-3 2C5/8A3 770 bql aviremic
RH2-13 1D4/5C1 900 bql aviremic
RH2-14 1B1/1D1 550 bql aviremic
RH2-22 2C2/1B4 670 bql aviremic
RH2-1 A8/D8 240 >500 viremic
RH2-5 2D11/2F10 120 110,000 viremic
RH2-7 B3/D6 10 >500 viremic
RH2-21 2B2/2F9 60 59,000 viremic
RH2-24 2F11 70 330,000 viremic
RH2-26 1C1 10 >500 viremic
PH2.1 C12/E6 200 >500 viremic
a Absolute CD4 T cell counts per μl blood.
b Copies of plasma viral RNA per milliliter.
c Grouped based on VLs.
d Usage of CCR5 or CXCR4 for viral entry.
e Number of vpx alleles sequenced per biological HIV-2 clone.
Abbreviations: PVL plasma viral load, Bql below quantifiable limit, n.k. not known.activation and found that the latter induced lower levels of
CD86 expression and IFN-γ secretion. Altogether, our re-
sults suggest that efficient Vpx-mediated SAMHD1 antag-
onism is advantageous for viral replication and not
associated with effective immune control in HIV-2-infected
individuals.
Results
Origin and sequence analysis of HIV-2 vpx alleles
The 20 vpx alleles analyzed in the present study were de-
rived from eleven HIV-2-infected individuals most of them
living near Rotterdam and belonging to West African im-
migrant communities [26-31]. One infected individual
(PH2) with detectable viremia was born and lived in
France [31]. The other patients were born in Ghana or the
Cape Verdean Islands, with the exception of RH2-26 who
is Caucasian [26-30]. Some virological and immunological
characteristics of these HIV-2-infected individuals have
been previously described [26-31] and are summarized in
Table 1. Four HIV-2-infected individuals, hereinafter re-
ferred to as effective controllers (ECs), maintained high
CD4+ T cell counts (>550/μl) and undetectable viral loads
(<500 viral RNA copies/ml) for 7.3 to 12.6 years, before
virus isolation for biological virus cloning [26-31]. Three
of these four ECs are still aviremic without treatment in
2012 (approximately ten years after isolation of the viruses
used in this study). In contrast, the seven viremic HIV-2
-infected individuals, named non-controllers (NCs), gener-
ally had low CD4 counts (<240/μl) and most of them suf-
fered from end stage AIDS at the time of virus isolation
(Table 1). RNA loads were available for five of the seven
individuals with progressive HIV-2 infection and ranged
from 4.36 to 5.52 log10 copies/ml. Thus, the EC and NCR5/X4d Group vpx allelese References
R5 A 3/3 [26-30]
R5 A 3/3 [26-30]
R5 A 3/3 [26-30]
R5 B 4/4 [26-30]
R5 A 3/6 [26-30]
R5 A 3/3 [26-30]
R5 A 3/3 [26-30]
n.k. A 3/3 [26-30]
R5/X4 A 3 [26-30]
R5/X4 A 8 [26-30]
n.k. A 3/3 [30,31]
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their ability to control viral replication.
To examine whether differences in virus control in HIV-
2-infected individuals are associated with differences in
Vpx function, we amplified PCR fragments encompassing
the vpx genes from biological HIV-2 clones obtained from
the patient samples. As described previously [26-30], these
HIV-2 clones were generated by co-cultivation of limiting
dilutions of PBMCs from HIV-2-infected donors with
PBMCs from seronegative donors. A total of 70 vpx genes
(3 to 8 for each HIV-2 clone) were sequenced. As expected,
vpx alleles derived from the same biological clone of HIV-10.2
1.0
1.0
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0.73
0.81
0
Figure 1 Evolutionary relationships among HIV-2 and SIV Vpx amino
study are highlighted in green (ECs) and red (NCs). Numbers on brancheswere highly homologous or identical. A total of 20 alleles
that encoded the respective consensus Vpx amino acid se-
quence of each of the twenty biological HIV-2 clones were
inserted into a CMV-promoter-based vector [32], which
co-expresses Vpx and eGFP from a bi-cistronic RNA. To
ensure that the vpx alleles were representative for each pa-
tient, we analyzed two biological HIV-2 clones from most
individuals, except for RH2-24 and RH2-26, where only
single biological clones were available for analysis (Table 1).
Sequence and phylogenetic analyses verified that all expres-
sion constructs contained the desired HIV-2 vpx alleles and
showed that those from ECs and NCs did not form distinctSIVrcm NG411
SIVrcm GAB
SIVmnd2 M14
SIVdrl FAQ
SIVmnd2 5440
SIVmnd2 CM16
SIVsmm SL92B
SIVmne 027
SIVstm 37.16
SIVsmm H635F
SIVsmm PGM53
HIV-2H 96FR12034
HIV-2G ABT96
SIVmac239
HIV-2B D205
HIV-2B 7312a
RH2-7 D6
RH2-7 B3
RPH2.1 C12
HIV-2A BEN
RH2-22 1B4
RH2-22 2C2
HIV-2B EHO
RH2-5-2F10
RH2-13 1D4
RH2-1 A8
RH2-3 2C5
RH2-1 D8
RH2-21 2B2
RH2-21 2F9
RH2-24 2F11
RH2-26 1C1
RH2-14 1B1
RH2-14 1D1
HIV-2A ROD9
HIV-2A ALI
RH2-5-2D11
RH2-13 5C1
HIV-2A ST
0.9
.42
0.68
0.74
0.88
0.89
B
A
RH2-3 8A3
acid sequences. HIV-2 Vpx sequences newly analyzed in the present
are percentage estimated posterior probabilities.
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group A, with the exception of RH2-22 that clustered with
HIV-2 group B strains (Figure 1).
Alignment of the deduced amino acid sequences sho-
wed that all vpx genes analyzed contained intact reading
frames that predicted full-length Vpx protein sequences
(Figure 2). The HIV-2 Vpx sequences showed a high
degree of conservation and those derived from the same
patient frequently only differed by single amino acid
changes. Several domains and residues previously described
to be critical for Vpx function, such as the C-terminal
stretch of seven proline residues that are critical for stable
Vpx expression [33,34], as well as a Wx4Φx2Φx3AΦxH
motif and residue Q76 involved in DCAF1 binding [35-37]
were preserved in all HIV-2 Vpx alleles analyzed, as well as
in published group A, B, G and H HIV-2 and SIVsmm/
mac/mne Vpx amino acid sequences (Figure 2). Unexpect-
edly, however, some variations were detected in a nuclear
localization signal (NLS) (SYTKYRYL) signal, which is im-
portant for nuclear import of Vpx [38-42]. Most notably, all
vpx alleles obtained from patient RH2-3 predicted a
SYTKYRYL to SYTMYRYL change (K68M) in this NLS
(Figure 2). Furthermore, vpx alleles derived from the RH2-7
D6 biological HIV-2 clone predicted an adjacent Y69F
substitution.
To determine the potency of vpx alleles from HIV-2-
infected individuals in degrading SAMHD1, we trans-
fected HeLa cells stably expressing Flag-tagged SAMHD1Figure 2 Alignment of HIV-2 and SIV Vpx sequences. The HIV-2 ROD V
helical regions, the nuclear localization signal (NLS), residue Q76 involved in
Dots indicate amino acid identity.with pCGCG constructs coexpressing Vpx and eGFP and
analyzed them by Western blot. Since no broadly reactive
HIV-2 Vpx-specific antibody is available, all Vpx proteins
were expressed with an C-terminal AU-1 tag in order to
monitor protein expression levels. In agreement with pub-
lished data [2-4], expression of the control SIVmac239
and HIV-2 ROD Vpx proteins strongly reduced the
steady-state expression levels of SAMHD1 compared to
cells transfected with the pCGCG construct expressing
only eGFP (Figure 3A). All Vpx proteins were expressed
at detectable levels and the great majority of them (18 of
20) clearly reduced the levels of SAMHD1 expression, al-
beit with variable efficiency. Only the RH2-3 2C5 and 8A3
vpx alleles that predicted the K68M mutation in the NLS
were inactive in degrading SAMHD1 (Figure 3A). In con-
trast, the RH2-7 D6 Vpx that contains the adjacent Y69F
change efficiently degraded SAMHD1 (Figure 3A).
Quantitative analyses showed that HIV-2 Vpx proteins
reduced the levels of SAMHD1 expression by up to two or-
ders of magnitude (Figure 3B). Some patient-derived HIV-2
Vpx alleles, such as RH2-13 5C1 and RH2-1 D8, were on
average even more potent in mediating SAMHD1 degrad-
ation than the control HIV-2 ROD and SIVmac239 Vpx
proteins. In contrast, the two HIV-2 RH2-3 2C5 and 8A3
Vpx alleles containing the K68M change were inactive
against SAMHD1 (Figure 3B). On average, vpx alleles de-
rived from NCs were more active in degrading SAMHD1
compared to those obtained from ECs (8.4±1.6%, n=39 vspx sequence is shown on top for comparison. The three putative α-
DCAF1 binding, and the C-terminal proline-rich region are indicated.
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Figure 3 Most HIV-2 Vpx proteins from controllers and non-controllers of virus replication degrade SAMHD1. (A) SAMHD1, ß-actin, eGFP
control and Vpx-AU-1 levels in HeLa cells stable expressing Flag-SAMHD1 with pCGCG constructs expressing the indicated HIV-2 Vpx proteins, the
control HIV-2 ROD or SIVmac239 Vpx alleles or only eGFP. Protein expression levels were determined by western blot two days post-transfection.
(B) Average levels of SAMHD1 in the presence of the indicated HIV-2 Vpx proteins. The SAMHD1 signals were obtained by western blot analysis
as described in panel A, quantified by Licor Odyssey software and normalized to the ß-actin signals. The graph shows mean values and standard
deviation (SD) of normalized SAMHD1 expression levels from four independent experiments. HIV-2 vpx genes were grouped based on the viral
loads of the patients and are color coded green (ECs) or red (NCs). (C) The levels of SAMHD1 expression were determined in stable transfected
HeLa cells in the presence of vpx alleles from HIV-2-infected ECs and NCs and are shown relative to those measured in the absence of
Vpx (100%).
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http://www.retrovirology.com/content/10/1/2731.7±9.2%, n=25; values gives percentages of SAMHD1 ex-
pression levels compared to the eGFP control [100%] and
represent means±SEM) (Figure 3C). However, this differ-
ence was just due to the lack of activity of the vpx alleles
derived from the EC RH2-3 (105.4±14.9) and failed to
reach significance. Thus, Vpx-mediated SAMHD1 degra-
dation was usually preserved in HIV-2-infected indIviduals
irrespectively of the efficiency of virus control.
Vpx alleles from viremic and aviremic individuals
promote macrophage infection
The results described above suggested that most HIV-2
Vpx proteins are active in promoting infection of mye-
loid cells by degrading SAMHD1. To directly determine
this, we first generated a vpx defective IRES-eGFP reporter
construct of SIVmac239. Similarly to previously described
HIV-1 NL4-3-based IRES-eGFP constructs [43,44], this
SIVmac239-based construct co-expresses Nef and eGFP via
an internal ribosome entry site and thus allows the conveni-
ent identification and quantification of virally infected cellsby flow cytometric analysis (examples shown in Figure 4A).
The SIVmac239 molecular clone was selected for these
studies because it is well characterized and expresses a fun-
ctional Vpx protein [3,4] that is highly homologous to those
of HIV-2 strains. Furthermore, SIVmac and HIV-2 belong
to the same lineage of primate lentiviruses and both are
genetically closely related and originated from SIVsmm
infecting sooty mangabeys [45,46]. Virus stocks were gener-
ated by cotransfection of 293T cells with a vpx-defective
SIVmac239 IRES-eGFP construct and pCGCG-based vec-
tors expressing the various HIV-2 Vpx proteins or eGFP
alone as a negative control. Predictably, mutation of vpx
severely impaired and co-expression of the mac239 Vpx
in the virus producer cells restored the capability of
SIVmac239 to infect primary human monocyte-derived
macrophages (MDM) (Figure 4A, B). The great majority of
HIV-2 Vpx proteins from both NCs and ECs efficiently res-
cued macrophage infection (Figure 4B). Predictable excep-
tions were the 8A3 and 2C5 vpx alleles from individual
RH2-3 that were unable to degrade SAMHD1 in HeLa cells
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Figure 4 HIV-2 Vpx-mediated enhancement of virus infection of macrophages. (A) Macrophages were transduced with the VSV-G
pseudotyped wild-type HIV-1 NL4-3 and SIVmac239 IRES-eGFP virions (panels 1 and 2) or a VSV-G pseudotyped vpx-defective SIVmac239 IRES-
eGFP construct produced in the presence of pCGCG vectors expressing eGFP alone (panel 3) or together with the indicated Vpx proteins (panels
4–10). Virus stocks were produced by transient transfection of 293T cells. High infection rates were associated with increased rates of apoptosis
and thus reduced numbers of cells analyzed in some experiments. (B) Average percentages and SDs of virally infected GFP+ cell levels detected
in macrophages derived from four different donors quantified by flow cytometric analysis at four days post-transduction. Virus infectivity was
normalized to infection of TZM-bl indicator cells. (C) Enhancement of macrophages infection by vpx alleles derived from HIV-2-infected
individuals grouped based on their viral loads and the infecting viruses. See legend to figure 3 for further detail.
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http://www.retrovirology.com/content/10/1/27(Figure 3). Thus, all HIV-2 Vpx proteins that degraded
SAMHD1 in transfection assays were also capable of pro-
moting macrophage infection. No antibodies against these
patient-derived Vpx proteins are available and the signals
obtained with the antibody against the AU-1 tag were too
weak to quantify virion incorporation (data not shown).
However, our finding that coexpression of a great majority
of these HIV-2 Vpx proteins in trans potently increased the
ability of the vpx-defective SIVmac construct to infect mac-
rophages implies that they were incorporated in the viral
particles. On average, vpx alleles from ECs and NCs of
HIV-2 infection were equally active in promoting macro-
phage infection (30.9±3.6%, n=24 vs 30.3±3.7, n=45; values
give mean ± SEM) (Figure 4C).
Substitution of K68M in the NLS impairs HIV-2 Vpx
function
As described above, two vpx alleles (RH2-3 8A3 and 2C5)
had little if any effect on SAMHD1 expression levels andfailed to promote macrophage infection. To determine
whether the K68M substitution was responsible for their
lack of activity, we mutated it back to 68K found in the
consensus NLS sequence (Figure 1). As shown in Figure 5-
A, all AU-1-tagged Vpx proteins were expressed at detect-
able levels. Substitution of M68K reduced the expression
levels of the RH2-3 2C5 Vpx but fully restored its capabil-
ity to degrade SAMHD1 and to promote macrophage
infection (Figure 5B, 5C). In comparison, substitution of
M68K in the RH2-3 8A3 Vpx increased these activities
only marginally. The 8A3Vpx differs from 2C5 by a total
of four amino acid changes (Figure 1). However, only a sin-
gle substitution of E15G distinguishes the 8A3 M68K Vpx
from functionally active Vpx proteins. Indeed, combined
substitutions of G15E and M68K restored the ability of the
RH2-3 8A3 Vpx to degrade SAMHD1 (Figure 5A, 5B). In
further support of a functional role of E15, substitution of
E15G impaired the anti-SAMHD1 activity of the HIV-2
ROD Vpx function. Unexpectedly, however, RH2-3 8A3
Figure 5 Effect of naturally occurring mutations in the NLS of HIV-2 Vpx proteins on SAMHD1 degradation and macrophage infection.
(A) HeLa cells stably expressing FLAG tagged SAMHD1 were mock transfected or transfected with constructs expressing the indicated AU-1
tagged Vpx proteins for 48 h before whole-cell extraction and analysis by western blot using the indicated antibodies. (B) Quantitation of Vpx-
mediated degradation of SAMHD1. Shown are the average levels and SEM of SAMHD1 expression in Hela cells in the presence of the indicated
Vpx alleles. Results were derived from four independent experiments. (C) MDM isolated from four donors were transduced by VSV-G-pseudotyped
SIVmac239 eGFP reporter viruses produced in the presence of the indicated Vpx proteins and GFP+ MDM were quantified four days later.
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inactive in promoting MDM infection (Figure 5C)
suggesting that it may not be efficiently incorporated into
progeny virions.
To determine the effect of alterations in the NLS of
HIV-2 Vpx proteins on the cellular distribution of Vpx and
SAMHD1, we transfected different Vpx expression con-
structs into HeLa cells which were stably expressing FLAG
tagged SAMHD1 and analyzed them by laser scanning
confocal microscopy. In agreement with published data
[4,47], SAMHD1 localized mainly to the nucleus in the ab-
sence of Vpx (Additional file 1: Figure S1, Additional file 2:
Figure S2). In cells expressing the SIVmac239 Vpx, the re-
sidual traces of SAMHD1 co-localized with Vpx within
yet-to-be-defined cytoplasmic compartments (Additional
file 1: Figure S1, Additional file 2: Figure S2 and data not
shown). Unexpectedly, the HIV-2 RH2-3 2C5 Vpx, which
contains the K68M substitution, re-localized SAMHD1
from the nucleus to the cytoplasm but was largely unable
to degrade it (Additional file 2: Figure S2D). In contrast,
the second Vpx allele derived from individual RH2-3
(8A3) localized throughout the cell and lacked both the
ability to re-localize and to degrade SAMHD1 (Additional
file 2: Figure S2F). Substitution of M68K resulted in a
strongly localized distribution of the RH2-3 2C5 Vpx pro-
tein at the cell’s edge and restored its capability to degrade
SAMHD1 (Additional file 2: Figure S2E). In comparison,
the RH2-3 8A3 M68K Vpx that displayed only modest
anti-SAMHD1 activity (Figures 3 and 4) showed diverse
effects; in some cells residual SAMHD1 was detected in
the nucleus (Additional file 1: Figure S1, Additional file 2:
Figure S2G and data not shown). Finally, combined substi-
tutions of G15E and M68K resulted in cytoplasmiclocalization of Vpx and effective degradation of SAMHD1
(Additional file 1: Figure S1, Additional file 2: Figure S2H).
The results obtained with the two RH2-3 HIV-2 vpx al-
leles suggested that the effect of the K68M change is to
some extent context dependent. To further examine this,
we also analyzed an HIV-2 ROD Vpx mutant containing
this substitution. The parental ROD Vpx showed a
punctuated cytoplasmic distribution and reduced the
levels of SAMHD1 expression below the detection limit
(Additional file 3: Figure S3A). Mutation of K68M resulted
in distribution of the ROD Vpx throughout the cell and
impaired its ability to degrade SAMHD1 (Additional file
3: Figure S3B). In comparison, substitution of E15G did
not affect the cytoplasmic localization of the ROD Vpx
but impaired its effect on SAMHD1 (Additional file 3:
Figure S3C). Altogether, these results show that resi-
due K68 plays a key role in Vpx-mediated SAMHD1
degradation and the subcellular localization of Vpx.
It has been previously suggested that HIV-2 may be ef-
fectively controlled in most infected individuals because it
activates innate antiviral immunity in dendritic cells [16].
To examine whether HIV-2 can activate DCs, we trans-
duced these cells with VSV-G-pseudotyped HIV-1 NL4-3
and HIV-2 ROD IRES-eGFP constructs in the presence or
absence of SIVmac239. As expected from previous data
[16], HIV-1 alone was unable to infect DCs and “enforced”
infection resulted in high levels of CD86 expression by
HIV-1-infected DCs (Figure 6A) and the secretion of high
levels of IFN-γ in the culture supernatant (Figure 6B). In
comparison, HIV-2-infected cells showed substantially
lower levels of CD86 expression than those infected with
HIV-1 (Figure 6A). Similarly, only low levels of IFN-γ
were detected in DC cultures infected with HIV-2 and/or
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similar in HIV-1/SIVmac (7.6±1.7%, n=4; mean value ±
SEM) and HIV-2/SIVmac (9.4±2.1%, n=4) exposed cul-
tures. Thus, similarly to SIVmac, HIV-2 did not induce
efficient activation and antiviral type I interferon re-
sponses in infected DC cultures.
Discussion
In the present study, we examined the function of Vpx
proteins derived from seven viremic HIV-2-infected
AIDS patients (NCs) and four long-term aviremic indi-
viduals (ECs) who did not develop immunodeficiency.
We found that efficient Vpx-mediated degradation of
SAMHD1 to promote myeloid cell infection is usually
preserved in both HIV-2-infected individuals that effi-
ciently control the virus as well as in individuals that
develop high viral loads and disease. SAMHD1 degrad-
ation could have both positive or negative effects on the
efficiency of HIV-2 replication in vivo. On the one hand
it allows efficient infection of macrophages and dendritic
cells and thus expands the number of viral target cells.
On the other hand it has been suggested that the effi-
ciency of SAMHD1 degradation by Vpx may contribute to
the effective control of viral replication in HIV-2 infected
individuals because viral immune sensing by infected den-
dritic cells may induce potent immune responses [16]. In
fact, particularly broad and potent innate and adaptive im-
mune responses have been observed in HIV-2-infectedM
o
ck
ca
m
VI
S+1-
VI
H
2-
VI
H
ca
m
VI
S+ 2-
VI
H
0
5000
10000
15000
20000
)I
F
M(
n
oisser
pxe
68
D
C
c a
m
VI
S
A
Figure 6 Effect of HIV-1 and HIV-2 on DC activation. (A) CD86 surface e
constructs alone or in combination with VSV-G-pseudotyped SIVmac239 pa
were measured at 3 days post-infection. Panels A and B show mean value
at detectable levels. (B) Levels of IFN-γ in the supernatant of the infected Dindividuals [17-20] and most of them efficiently control
viral replication and become long-term non-progressors
[21-25]. However, our finding that major differences in
the efficiency of control of HIV-2 replication in infected
individuals were not associated with significant differences
in the potency of Vpx-mediated SAMHD1 degradation
argues against a major role of this mechanism in the
virological and clinical outcome of HIV-2 infection. Not-
ably, it has recently been shown that polymorphisms in
SAMHD1 are not associated with immune control in
HIV-1-infected individuals, although it remained to be de-
termined whether these polymorphisms affect viral infec-
tion of myeloid cells and immune sensing in vitro [48].
It has been previously reported that HIV-2 infection
activates dendritic cells (DCs) in a CypA dependent
manner and thus suggested that efficient infection and
activation of DCs may contribute to the effective control
of viral replication in most HIV-2 infected individuals
[16]. If this hypothesis is correct, HIV-2 strains that are
associated with high viral load and AIDS (similarly to
most HIV-1 infections) should show a reduced capability
to infect myeloid cells and thus lack a potent SAMHD1
antagonist (like HIV-1). We found, however, that
this is not the case because Vpx-mediated degradation of
SAMHD1 was preserved in all biological viral clones de-
rived from seven HIV-2-infected individuals that developed
high viral loads and progressed to AIDS. These data
suggest that Vpx-mediated degradation of SAMHD1 toM
o
ck ca
m
V I
S+1 -
V I
H
2-
V I
H
ca
m
VI
S+2-
VI
H
ca
m
VI
S
0.0
0.5
1.0
1.5
)l
m/
g
n(
-
N
FI
B
xpression in DCs after infection with HIV-1 and HIV-2 IRES-eGFP
rticles. The levels of CD86 expression by virally infected (eGFP+) cells
s (±SEM) derived from four experiments. HIV-1 alone did not infect DCs
C cultures.
Yu et al. Retrovirology 2013, 10:27 Page 9 of 14
http://www.retrovirology.com/content/10/1/27facilitate myeloid cell or resting T cell infection is usually
advantageous for HIV-2 replication in vivo and not associ-
ated with improved immune control. In agreement with
this possibility, we found that (unlike HIV-1) HIV-2 does
not efficiently activate antiviral innate immunity in infected
dendritic cells. It has been shown that HIV-1-induced acti-
vation of innate anti-viral immunity in DCs requires the
interaction of newly synthesized viral capsid with CypA
[16]. Whether or not the HIV-2 capsid can bind to CypA
is under debate. One study reported interaction, albeit with
much lower affinity than the HIV-1 capsid [49]. Others,
however, documented that neither HIV-2 nor SIVmac re-
cruit CypA into their cores and showed that drugs that
block CA-CypA interactions do not affect the titers of
these viruses [50]. In agreement to the results of the previ-
ous report [16], we found that VSV-G-pseudotyped
SIVmac239 virus-like particles alone did not efficiently in-
duce dendritic cell activation (Figure 6). SIVmac and HIV-
2 are closely related and have a common ancestor with
SIVsmm infecting sooty mangabeys [45,46,51]. Thus, it
seems plausible that both do not activate antiviral innate
immunity in human dendritic cells, particularly since one
would expect selection against effective immune sensing
during adaptation of HIV-2 to humans. More comprehen-
sive comparative studies on innate immune sensing of vari-
ous HIV-1 and HIV-2 strains will be necessary to clarify
this issue. Notably, it has been reported that DCs are actu-
ally more susceptible to HIV-1 than to HIV-2 infection
[52]. Thus, further studies using primary HIV-2 strains
seem highly warranted, particularly since delivery of large
quantities of Vpx by viral-like particles (VLPs) into the
viral target cells bears the risk of artifacts. In either case
our findings that the potency of SAMHD1 antagonism and
virus control do not correlate and that HIV-2 did not effi-
ciently activate DCs, suggest that immune sensing of HIV-
2 by infected human DCs may be usually too ineffective to
induce protective immune responses.
The only two vpx alleles that were inactive in antagoniz-
ing SAMHD1 and failed to boost myeloid cell infection
were both derived from individual RH2-3, who efficiently
controlled viral replication. This preliminary finding
suggests that counteraction of SAMHD1 may be counter-
selected against in a small subset of HIV-2-infected individ-
uals. Thus, it will be interesting to further examine whether,
similarly to HIV-1 [16], a minority of HIV-2 strains may ac-
tivate antiviral innate immunity in DCs and thus lose the
SAMHD1 degradation function of Vpx to facilitate viral
immune evasion. The viral accessory proteins are well
known for their functional plasticity [7-9] and some pri-
mate lentiviruses utilize Vpr to antagonize SAMHD1 [13].
Thus, the possibility that some HIV-2 strain may utilize
Vpr instead of Vpx to counteract SAMHD1 can also not
be dismissed entirely and may warrant further investiga-
tion. It will also be of interest to determine whether Vpx-mediated counteraction of SAMHD1 may be counter-
selected against in individuals with dual HIV infection.
Co-infection of DCs with SIVmac and HIV-1 in vitro
resulted in efficient activation and induction of a type I IFN
response because delivery of Vpx by SIV virions eliminates
the restriction to HIV-1 infection [16]. It is conceivable that
HIV-2-mediated delivery of Vpx into DCs may also
increase their susceptibility to HIV-1 infection in vivo in
dually infected individuals. The resulting increased activa-
tion of innate and adaptive immune responses may
enhance viral control and promote the selection of HIV-2
variants lacking the SAMHD1 degradation function of
Vpx. Recently, it has been reported that an HIV-1 super-
infection in an HIV-2-infected women resulted in efficient
control of HIV-1 replication [53]. This case is quite remark-
able because the patient did not show HIV-associated dis-
ease and maintained low HIV-1 and undetectable HIV-2
RNA levels during the entire observation period of six
years and in the absence of anti-retroviral therapy [53]. It
would have important implications for vaccine develop-
ment and strategies to improve immune control if in-
creased HIV-1 infection of myeloid cells by antagonism of
the SAMHD1 would indeed lead to improved innate and
adaptive immune responses that are associated with effect-
ive virus control. Dual HIV infections are not uncommon
in West Africa [25,54,55] and future studies of Vpx func-
tion and the virological and clinical outcome of infection in
these individuals seem highly warranted.
Currently, the exact mechanism of Vpx-mediated
SAMHD1 antagonism is not fully understood reviewed
in [56-59]. In agreement with the recent finding that
Vpx-mediated degradation of SAMHD1 seems to be ini-
tiated in the nucleus [47], our data suggest that all active
Vpx alleles analyzed in the present study may be capable
of interacting with SAMHD1 in the nucleus to relocalize
it to the cytosol of the cell for degradation. Some active
Vpx proteins colocalized with SAMHD1 throughout the
cytoplasm, whereas others resulted in a compartmental-
ized localization of Vpx and SAMHD1 towards the lead-
ing edges of the cell (Additional file 1: Figure S1,
Additional file 2: Figure S2G and data not shown). An ob-
vious limitation of these microscopic analyses is that
effective SAMHD1 degradation by some Vpx proteins
makes it difficult to define the subcellular localization of
the former in the presence of Vpx. Thus, e.g. the possibil-
ity that SAMHD1 is efficiently degraded by Vpx in the
nucleus and thus mainly detectable in the cytoplasm can-
not be dismissed entirely but seems unlikely since all ac-
tive Vpx protein showed a cytoplasmic localization. All six
vpx alleles derived from two biological HIV-2 clones
obtained from individual RH2-3 predicted a substitution
of K68M in a putative NLS. This alteration generally
disrupted the effect of Vpx on SAMHD1 and macrophage
infection without reducing the steady state expression
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dependent. The presence of K68M in the RH2-3 8A3 and
ROD Vpx proteins impaired their capability to relocalize
and to degrade SAMHD1 (Figure 5, Additional file 1: S1
to Additional file 3: Figure S3). In contrast, the RH2-3
2C5 Vpx relocalized SAMHD1 from the nucleus to the
cytoplasm but failed to degrade it efficiently. The mecha-
nisms underlying these different phenotypes need further
investigation.
In the present study we utilized an SIVmac construct to
study the effect of HIV-2 Vpx on viral infectivity for mac-
rophages. Since this may raise the concern that some HIV-
2 Vpx proteins may not be efficiently incorporated into
heterologous SIVmac particles, we also attempted to gen-
erate analogous proviral constructs of the group A HIV-2
ROD clone. The wild-type HIV-2 ROD IRES-eGFP con-
struct was infectious for macrophages and utilized in the
studies on viral immune sensing (Figure 6). Unfortunately,
the vpx-defective HIV-2 ROD derivative was generally
poorly infectious even in highly susceptible TZM-bl indica-
tor cells and thus not suitable for functional studies (data
not shown). We do not feel, however, that utilization of
SIVmac compromises the main conclusions of our study.
It is noteworthy, that some HIV-2 strains are actually more
closely related to SIVmac (that has the same origin) than
to one another since HIV-2 resulted from several zoonotic
transmission of SIVsmm to humans [51]. Moreover,
the dileucine-containing motif (D-X-A-X-X-L-L) in
the N-terminal half of p6gag that is required for Vpx
incorporation into viral particles is highly conserved
in the HIV-2/SIVsmm/SIVmac group [60]. In fact, we
found that 18 of 20 HIV-2 Vpx proteins efficiently
increased the ability of SIVmac to infect macrophages,
which implies that they were incorporated into the virions.
The two inactive Vpx proteins (RH2-3 2C5 and 8A3)
contained mutations in their NLS and were unable to
degrade SAMHD1. In one case ineffective virion incorpor-
ation may have contributed to the lack of activity of the
RH2-3 8A3 Vpx since changes of E15G and K68M
restored its ability to degrade SAMHD1 but not to
promote macrophage infection (Figure 5).
Our finding that all 12 vpx alleles derived from seven
NCs degraded SAMHD1 and promoted macrophage in-
fection strongly suggests that potent infection of myeloid
cells is usually not associated with effective immune
control of HIV-2. However, studies of vpx alleles from
larger numbers of HIV-2-infected individuals are neces-
sary to clarify whether exceptions may exist. For ex-
ample, it will be interesting to determine whether HIV-2
capsids may differ in their interaction with CypA and
the induction of innate immune responses and whether
such differences affect the functionality of Vpx in
infected individuals. Furthermore, it will be of interest to
examine if co-infection with HIV-2 relieves therestriction of DCs to HIV-1 infection by Vpx-delivery
and induces potent antiretroviral immune responses
in vivo. A better understanding of how both viruses
affect one another and especially whether HIV-2-assisted
increased HIV-1 infection of DCs may induce protective
immune responses may yield important information for
immunotherapy and vaccine approaches.
Conclusions
Our data suggest that Vpx-mediated degradation of
SAMHD1 to promote myeloid cell infection is usually
preserved and thus advantageous in both viremic and
aviremic HIV-2-infected individuals. In agreement with
this observation, we found that HIV-2 ROD does not in-
duce potent activation of infected DCs. Together, these
results suggest that differences in the efficiency of mye-
loid cell infection and immune sensing are not the main
reason why some HIV-2-infected individuals efficiently
control the virus, whereas others develop high viral loads
and progress to AIDS.
Methods
Patients
Vpx genes were derived from eleven individuals from
the Rotterdam cohort. The characteristics of these pa-
tients and the determination of CD4+ T cell numbers
and plasma viral loads have been described previously
[26-31] and are summarized in Table 1. Viremic HIV-2-
infected individuals (NCs) were defined as having a plas-
ma viral load >500 copies per ml, and non-viremic
subjects (ECs) were defined as having viral loads <500
copies per ml. All HIV-2 infected individuals examined
were seronegative for HIV-1. With the exception of one
individual (RH2-22), who was infected with HIV-2 sub-
type B all individuals were infected with subtype A. All
study participants provided informed consent and the
studies were approved by the local Ethical Committees.
Generation of HIV-2 vpx alleles
Genomic viral RNA genomes were extracted from bio-
logical HIV-2 clones isolated as described previously
[30,31]. In brief, these HIV-2 clones were generated by
co-cultivation of limiting dilutions of PBMCs from HIV-
2-infected donors with PBMCs from seronegative do-
nors. Vpx-vpr fragments were amplified by RT-PCR
using the cDNA primers (p5’;vpx2, 5`-CAGGTACCRT
CACTTCAATTYCTRGCCYTAG-3 and p3’vpr2, 5`-CT
GGCAATGGTAG-CAGCATYGCTTACAATAGCA-3`).
PCR amplification products were cloned in the TOPO-
TA vector (Invitrogen) and three to eight clones were
sequenced to identify one representing the consensus
sequence of the respective biological HIV-2 clone. Sub-
sequently, the selected vpx genes were amplified by PCR
using primers introducing flanking XbaI and MluI sites
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expression levels of Vpx a 3`primer introducing a C-
terminal AU-1 tag was used for PCR amplification. The
accuracy of all PCR-derived inserts was confirmed by se-
quence analysis.
Proviral constructs
Generation of SIVmac239-based proviral constructs
carrying a functional or disrupted vpx gene and a nef
reading frame followed by an internal ribosome entry
site (IRES) and the eGFP gene were generated essen-
tially as previously described for analogous HIV-1-based
constructs [43,44].
Cell culture
293T cells, TZM-bl cells and HeLa cells stably expressing
Flag-SAMHD1 were maintained in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% FCS plus
2 mM glutamine and 100 Unit/ml Penicillin-Streptomysin.
PBMC from healthy human donors were isolated using
lymphocyte separation medium (Biocoll Separating Solu-
tion, Biochrom), stimulated for 3 days with PHA (2 μg/ml)
and cultured in RPMI1640 medium with 10% FCS and 10
ng/ml IL-2 prior to infection. MDMs were generated from
PBMCs by 7 days stimulation with 50 ng/ml of either
recombinant human granulocyte-macrophage colony-
stimulating factor (rhGM-CSF, R&D Systems) or macro-
phage colony-stimulating factor (M-CSF, R&D Systems)
and cultured in RPMI1640 medium with 10% FCS. Phyco-
erythrin (PE) conjugated monoclonal antibody against
CD163 (556018, BD Biosciences) and CD206 (555954, BD
Biosciences) were used to verify the phenotype and purity
of differentiated MDMs as described [61].
Immunoblot analysis for SAMHD1 degradation
HeLa cells stably expressing Flag-SAMHD1 were trans-
fected with 4 μg of pCG-Vpx-EGFP expression constructs
using polymer-based DNA trasnfection reagents (JetPEI™,
Polyplus Transfection) following standard protocols of the
manufacturer. At 48 h post-transfection cells were lysed in
RIPA buffer containing protease inhibitor cocktail and
then normalized for protein concentration. Whole-cell ly-
sates containing 20 μg total proteins were separated on
4-12% Bis-Tris gradient acrylamide gels, transferred onto
a polyvinylidene difluoride (PVDF) membrane and probed
with a mixture of mouse monoclonal antibody to Flag
(1:1000, Sigma) and Actin (1:2000, ab3280, Abcam) and
rabbit polyclonal to GFP (1:1000, ab290, Abcam). Subse-
quently, blots were probed with anti-mouse or anti-rabbit
IRDye Odyssey antibodies (926–32210, 926–32221). Pro-
teins were revealed using a LI-COR Odyssey scanner and
quantification of the signal intensities were analyzed by
the Odyssey software. The ratios of SAMHD1 to ß-actinsignal intensities were used to determine the efficiencies
of Vpx-mediated SAMHD1 degradation.
Virus production and MDMs transduction
Viral particles were produced from HEK 293T cells
using the standard calcium phosphate transfection pro-
tocol [40]. For VSV-G HIV-1-eGFP production, 293T
cells were transfected with 5 μg HIV-1 NL4-3 IRESeGFP
and 0.8 μg VSV-G encoding plasmid; for Vpx incorpor-
ation, 1.2 μg pCG-Vpx-eGFP was co-transfected with 5
μg SIVmac239 ΔVpx-eGFP and 0.8 μg VSV-G encoding
plasmid. Medium was replaced 16 h post-transfection
and viruses were harvested 24 h later. The yield of infec-
tious virus was determined by infection of TZM-bl indica-
tor cells. Briefly, 8,000 cells were seeded in 96-well plate,
after overnight incubation, cells were transduced with 100
μl VSV-G pseudotyped virus for 3 days and harvested for
eGFP detection by flow cytometry using FACS CantoII.
For MDMs transduction, 2.5 × 105 cells were transduced
with 800 μl VSV-G pseudotyped virus. After overnight
incubation the medium was replaced with fresh medium
and the MDMs were cultured for additional 4 days and
infection rates were determined by flow cytometric detec-
tion of eGFP+ cells. The infectivity of each virus in MDMs
was normalized to TZM-bl infectivity, the relative infec-
tion rate of SIVmac239 was set to 100%.
Western blot
To monitor Vpx expression, HeLa or 293T cells were
transfected with 4 μg of vector DNA co-expressing AU1-
tagged Vpx and eGFP. Next day, cells were harvested and
lysed in RIPA (1% NP-40, 0.5% Na-DOC, 0.1% SDS, 0.15 M
NaCl, 50 mM Tris–HCl [pH 7.4], and 5 mM EDTA), and
cell lysates were separated in 12% SDS-polyacrylamide
(PAA) gels in a Tris-Tricine buffer system. After gel electro-
phoresis, proteins were transferred onto PVDF membranes
and probed with AU1 (PRB-130P, Covance) and β-actin
(8227–50, Abcam). For transfection control, another
gel was run with similar conditions, after blotting the
membrane was incubated with antibody specific for GFP
(290–50, Abcam). Subsequently, blots were probed with
anti-mouse or anti-rabbit IRDye Odyssey antibodies (926–
32210, 926–32221) and proteins revealed using a LI-COR
Odyssey scanner.
Confocal microscopy
Immunofluorescence was performed as described ear-
lier [62]. Briefly, HeLa cells stably expressing FLAG tagged
SAMHD1 were cultivated on 8-well Ibidi slides (Ibidi
GmbH). On the next day, cells were transfected with 150
ng of plasmid DNA expressing AU1 tagged Vpx. At 16–18
h post-transfection, cells were fixed with 4% paraformalde-
hyde for 30 min and stained by indirect immunofluores-
cence. After washing with phosphate-buffered saline (PBS),
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and mouse MAb against FLAG tag (1:500, Abcam) in PBS
containing 0.25% fish skin gelatin (Sigma), 0.2% bovine
serum albumin (BSA), and 0.2% saponin for 2 h. Cells were
washed again with PBS, incubated with Alexa Flour 568-
conjugated goat anti-rabbit IgG and Alexa Flour 647-
conjugated goat anti-mouse IgG (both 1:500 dilution;
Invitrogen-Life Technologies) for another 2 h, washed
again, and stained by Hoechst 33342. Images were ac-
quired on an LSM 710 confocal microscope (Carl Zeiss,
Germany) with Zeiss Zen 2010 software.Phylogenetic analysis
Vpx amino acid sequences were obtained from the Los
Alamos HIV Sequence Database (http://hiv-web.lanl.gov).
Phylogenetic trees were constructed using PhyML by
the ML method (http://www.phylogeny.fr/version2_cgi/
index.cgi).DCs activation and IFN-γ release assay
DCs were generated from PBMCs by 3 days stimulation
with 50 ng/ml of rhGM-CSF and 25 ng/ml of IL-4 (R&D),
and cultured in RPMI1640 medium with 10% FCS. Viral
particles were produced from HEK 293T cells using the
standard calcium phosphate transfection protocol. Briefly,
293T cells were transfected with 5 μg HIV-1 NL4-3 IRES-
eGFP, SIVmac 239 IRES-eGFP, HIV-2 ROD IRES-eGFP
and 0.8 μg VSV-G encoding plasmid. Medium was
replaced 16 h post-transfection and viruses were harvest
24 h later. For DCs transduction, 2 × 105 cells were trans-
duced with 100 μl VSV-G pseudotyped virus, either alone
or in combination. After 6 h incubation, the medium was
replaced with fresh medium and the DCs were cultured
for additional 72 hs. Infection rate was determined by de-
tection of eGFP+ cells. DC activation was measured using
the APC conjugated monoclonal antibody against CD86
(5397868, Invitrogen) by flow cytometry. Infectious super-
natant was collected for measuring the interferon-γ
release using the human IFN-γ ELISA kit, as described in
the manufacturing handle book (Human IFN-γ ELISA Kit,
RayBiotech).Ethics statement
Written informed consent was provided by all study par-
ticipants or their legal guardians. Ethical approval was
obtained from the Ethics Committee of the University
Hospital Centre Rotterdam, Rotterdam, The Netherlands.Accession numbers
HIV-2 vpx sequences will be submitted to GenBank and
accession numbers will be provided upon acceptance of
the manuscript.Additional files
Additional file 1: Figure S1. Redistribution and degradation of
SAMHD1 by HIV-2 Vpx proteins. (A-K) Overview images from two
different regions of HeLa cells stably expressing FLAG tagged SAMHD1,
transfected with 150 ng of plasmid expressing the indicated AU1-tagged
Vpx. Cells were stained for SAMHD1 (red), Vpx (green) and nucleus (blue)
as described in the methods section. Scale bars represent 50 μm.
Additional file 2: Figure S2. Redistribution and degradation of
SAMHD1 by HIV-2 Vpx proteins. (A-H) HeLa cells stably expressing FLAG
tagged SAMHD1 were transfected with 150 ng of plasmid expressing the
indicated AU1-tagged Vpx. At 16–18 h post-transfection, cells were fixed
and permeabilized and Vpx was detected using a rabbit anti AU1 and
SAMHD1 was detected using a mouse anti-FLAG-tag, respectively. Scale
bars represent 10 μm.
Additional file 3: Figure S3. Effect of E15G and K68M substitutions on
HIV-2 ROD Vpx localization and function. (A-C) HeLa cells were
transfected with constructs expressing FLAG tagged SAMHD1 and the
indicated AU1-tagged Vpx and analyzed as described in the legend to
Figure 6. Scale bars represent 10 μm.
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